GlassScriptPhysician profile
Elizabeth E Anderson
NPI 1922077445
$5,130.90
in general payments reported to CMS, 2019-2025
23 companies · $1,054 in 2025
The $1,054 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $880 · 2022: $225 · 2023: $924 · 2024: $2,048 · 2025: $1,054.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,879 · Education: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,878.57 |
| Education | $147.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,843.38 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia, Pascal |
| Abbott Laboratories | $670.21 | 2021-2025 | Amplatzer Amulet, Triclip |
| Amgen INC. | $401.61 | 2022-2024 | Repatha |
| Pfizer INC. | $267.63 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $254.72 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $243.26 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.09 | 2023-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $193.69 | 2021-2023 | Farxiga |
| Actelion Pharmaceuticals US, INC. | $143.85 | 2021-2024 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $115.56 | 2023-2024 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $96.35 | 2021-2023 | Eliquis |
| Janssen Pharmaceuticals, INC | $92.04 | 2021-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $87.56 | 2021-2024 | Lifevest |
| Heartflow, INC. | $86.49 | 2025 | |
| Janssen Scientific Affairs, LLC | $80.93 | 2023 | Xarelto |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $64.01 | 2021-2024 | |
| Scpharmaceuticals INC. | $63.72 | 2023-2024 | |
| Esperion Therapeutics, INC. | $49.31 | 2023-2024 | Nexletol |
| Impulse Dynamics (USA) INC. | $47.94 | 2023 | Optimizer |
| Medtronic, INC. | $45.97 | 2025 | Corevalve Evolut R |
| Lexicon Pharmaceuticals, INC. | $43.31 | 2023-2024 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $28.24 | 2024 | Arcalyst |
| Philips North America LLC | $15.03 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.